The Lymphoma Channel is supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASH 2021 | CD5.CAR T-cell therapy in patients with T-cell lymphoma
LaQuisa Hill, MD, Texas Children’s Hospital, Houston Methodist Hospital, Houston, TX, presents updates from a Phase I trial (NCT03081910) assessing autologous CD5-specific chimeric antigen receptor (CD5.CAR) T-cell therapy in patients with T-cell lymphoma. In a cohort of nine patients who were treated, an increased dose level was administered and encouraging responses were reported, with three patients being able to proceed to transplant. Dr Hill additionally highlights changes in the manufacturing process since data were first reported. This interview took place at the 63rd ASH Annual Meeting and Exposition congress in Atlanta, GA.
